Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy.
Jorge E CortesHagop M KantarjianMichael J MauroFiona AnSonja NickEric LeipCarlo Gambacorti-PasseriniTim H BrümmendorfPublished in: European journal of haematology (2021)
The incidence of cardiac, hypertension, vascular, and effusion events was low in patients with Ph+ CML resistant or intolerant to prior therapy who were treated with bosutinib.